Web Content Viewer

Actions

Canon U.S. Life Sciences Enters Into Collaborative Agreement With T2 Biosystems

Collaboration Aims to Develop a Diagnostic Test Panel for the Detection of Lyme Disease


ROCKVILLE, MD., February 3, 2015 - Canon U.S. Life Sciences, Inc., a subsidiary of Canon U.S.A., Inc., has entered into a collaborative agreement with T2 Biosystems, Inc. to develop a diagnostic test panel for rapidly detecting Lyme disease, a tick-born bacterial infection that can cause joint inflammation, neurological disorders and cognitive defects. This project can positively impact outcomes for patients through improved diagnostics on an infection where delays can result in significant illness.

"Through our continued efforts in developing innovative diagnostic solutions, we are excited to partner with T2 Biosystems to be able to address a critical need in the detection of Lyme disease. We look forward to working together to bring this product to market," said Akiko Tanaka, vice president and COO, Canon U.S. Life Sciences, Inc. "Canon U.S. Life Sciences is committed to improving human health and this project is a positive step in achieving our mission."

"We are delighted to partner with the team at Canon U.S. Life Sciences in the development of a T2 Magnetic Resonance (T2MR)-based diagnostic panel for the rapid detection of Lyme disease," said John McDonough, president and CEO of T2 Biosystems. "We believe our T2MR technology platform has the potential to provide accurate diagnostic results in hours versus weeks which may result in improved outcomes for patients while reducing the costs of treating this debilitating disease."

For additional information on Canon U.S. Life Sciences, Inc., visit www.culs.canon.com.

About Canon U.S. Life Sciences, Inc.

Founded in 2002 and located in Rockville, Maryland, Canon U.S. Life Sciences, Inc., is a subsidiary of Canon U.S.A., Inc., dedicated to identifying and developing diagnostic solutions to help address unmet medical needs and improving human health.

About Canon U.S.A., Inc.

Canon U.S.A., Inc., is a leading provider of consumer, business-to-business, and industrial digital imaging solutions to the United States and to Latin America and the Caribbean (excluding Mexico) markets. With approximately $36 billion in global revenue, its parent company, Canon Inc. (NYSE:CAJ), ranks third overall in U.S. patents granted in 2014† and is one of Fortune Magazine's World's Most Admired Companies in 2014. In 2014, Canon U.S.A. has received the PCMag.com Readers' Choice Award for Service and Reliability in the digital camera and printer categories for the 11th consecutive year. Canon U.S.A. is committed to the highest level of customer satisfaction and loyalty, providing 100 percent U.S.-based consumer service and support for all of the products it distributes. Canon U.S.A. is dedicated to its Kyosei philosophy of social and environmental responsibility. In 2014, the Canon Americas Headquarters secured LEED® Gold certification, a recognition for the design, construction, operations and maintenance of high-performance green buildings. To keep apprised of the latest news from Canon U.S.A., sign up for the Company's RSS news feed by visiting www.usa.canon.com/rss and follow us on Twitter @CanonUSA. For media inquiries, please contact pr@cusa.canon.com.

About T2 Biosystems

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.

Forward-Looking Statements for T2 Biosystems

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on the current expectations of the management of T2 Biosystems, Inc. ("T2 Bio"). These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of any diagnostic products and the ability to bring such products to market. With respect to T2 Bio, these and other important factors discussed under the caption "Risk Factors" in T2 Bio's final prospectus filed with the Securities and Exchange Commission, pursuant to Rule 424(b) of the Securities Act of 1933, as amended, on August 7, 2014, and in T2 Bio's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2014, could cause actual results of T2 Bio to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent the estimates of the management of T2 Bio as of the date of this press release. While T2 Bio may elect to update such forward-looking statements at some point in the future, each disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing T2 Bio's views as of any date subsequent to the date of this press release.

###
 

† Based on weekly patent counts issued by United States Patent and Trademark Office.

All referenced product names, and other marks, are trademarks of their respective owners.